EC Number   |
Inhibitors |
Structure |
|---|
    1.4.3.22 | (E)-1,4-diamino-2-butene |
0.1 mM, 72% and 87% inhibition; 0.1 mM, 72% and 87% inhibition |
   |
| 1.4.3.22 | (Z)-1,4-diamino-2-butene |
0.1 mM, 28% inhibition; 0.1 mM, 28% inhibition |
|
| 1.4.3.22 | (Z)-1,4-diamino-2-butene |
- |
|
| 1.4.3.22 | (Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride |
i.e. LJP 1586. Potent, specific, and orally available inhibitor of SSAO activity is an effective anti-inflammatory compound in vivo |
|
| 1.4.3.22 | 1,10-phenanthroline |
10 mM, 47% inhibition |
|
| 1.4.3.22 | 1,3-diaminopropane |
10 mM with 2 mM N-methylputrescine as substrate, 32% relative inhibition |
|
| 1.4.3.22 | 1,3-diaminopropane |
10 mM with 2 mM N-methylputrescine as substrate, 70% relative inhibition |
|
| 1.4.3.22 | 1,3-diaminopropane |
10 mM with 2 mM N-methylputrescine as substrate, 93% relative inhibition |
|
| 1.4.3.22 | 1,3-diaminopropane |
- |
|
| 1.4.3.22 | 1,4-Diamino-2-butanone |
- |
|
